Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

Elihu H. Estey, Francis J. Giles, Miloslav Beran, Susan O'Brien, Sherry A. Pierce, Stefan H. Faderl, Jorge E. Cortes, Hagop M. Kantarjian

Research output: Contribution to journalArticle

150 Scopus citations

Abstract

We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m 2 day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/μL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m 2 every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84%). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible.

Original languageEnglish (US)
Pages (from-to)4222-4224
Number of pages3
JournalBlood
Volume99
Issue number11
DOIs
StatePublished - Jun 1 2002
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Estey, E. H., Giles, F. J., Beran, M., O'Brien, S., Pierce, S. A., Faderl, S. H., Cortes, J. E., & Kantarjian, H. M. (2002). Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood, 99(11), 4222-4224. https://doi.org/10.1182/blood-2001-12-0174